Injectable Recombinant Human Neuregulin-1(Neucardin™) is a “First-in-Class” genetic engineering biologic product developed by Zensun (Shanghai) Sci & Tech Co. Ltd. for treatment of mild to moderate chronic heart failure (CHF). Zensun launched its phase III clinical trial (project ZS-01-305) in 2012, and has enrolled 679 patients as of the Interim analysis. Zensun authorized PAREXEL China Co. Ltd. to initiate the Interim analysis of this trial, whose statistical results will be released soon after all date is unblinded and analyzed.

Neucardin™ Phase III clinical trial (ZS-01-305, NCT01541202) is a randomized, parallel, placebo-controlled, double-blind, Chinese multi-center registration study to evaluate the efficacy of Neucardin™ on mortality rate reduction in target chronic systolic heart failure patients based on the clinical standard therapy. It is a significant late-stage clinical trial to observe the efficacy of Neucardin™ on mortality rate reduction.

About Recombinant Human Neuregulin-1(Neucardin™)

Injectable Recombinant Human Neuregulin-1(Neucardin™) is a “First-in-Class” genetic engineering biologic product developed by Zensun (Shanghai) Sci & Tech Co. Ltd. for treatment of mild to moderate chronic heart failure (CHF). The advantage of Neucardin™ is that it can specifically target the cardiac muscle cell, repair the cell structure and improve function during heart contraction and relaxation, thereby improving cardiac function and reversing pathological ventricular remodeling, and significantly reducing mortality rate and readmission rate while improving the quality of life. Neucardin™ is one of Chinese “First-in-Class” new drugs based on novel mechanism.